|
Public Act 099-0711 |
HB4462 Enrolled | LRB099 16680 NHT 41018 b |
|
|
AN ACT concerning public health.
|
Be it enacted by the People of the State of Illinois,
|
represented in the General Assembly:
|
Section 1. Short title. This Act may be cited as the |
Epinephrine Auto-Injector Act. |
Section 5. Definitions. As used in this Act: |
"Administer" means to directly apply an epinephrine |
auto-injector to the body of an individual. |
"Authorized entity" means any entity or organization, |
other than a school covered under Section 22-30 of the School |
Code, in connection with or at which allergens capable of |
causing anaphylaxis may be present, including, but not limited |
to, independent contractors who provide student transportation |
to schools, recreation camps, colleges and universities, day |
care facilities, youth sports leagues, amusement parks, |
restaurants, sports arenas, and places of employment. The |
Department shall, by rule, determine what constitutes a day |
care facility under this definition. |
"Department" means the Department of Public Health. |
"Epinephrine auto-injector" means a single-use device used |
for the automatic injection of a pre-measured dose of |
epinephrine into the human body. |
"Health care practitioner" means a physician licensed to |
|
practice medicine in all its branches under the Medical |
Practice Act of 1987, a physician assistant under the Physician |
Assistant Practice Act of 1987 with prescriptive authority, or |
an advanced practice nurse with prescribing authority under |
Article 65 of the Nurse Practice Act. |
"Pharmacist" has the meaning given to that term under |
subsection (k-5) of Section 3 of the Pharmacy Practice Act. |
"Undesignated epinephrine auto-injector" means an |
epinephrine auto-injector prescribed in the name of an |
authorized entity. |
Section 10. Prescription to authorized entity; use; |
training. |
(a) A health care practitioner may prescribe epinephrine |
auto-injectors in the name of an authorized entity for use in |
accordance with this Act, and pharmacists and health care |
practitioners may dispense epinephrine auto-injectors pursuant |
to a prescription issued in the name of an authorized entity. |
Such prescriptions shall be valid for a period of 2 years. |
(b) An authorized entity may acquire and stock a supply of |
undesignated epinephrine auto-injectors pursuant to a |
prescription issued under subsection (a) of this Section. Such |
undesignated epinephrine auto-injectors shall be stored in a |
location readily accessible in an emergency and in accordance |
with the instructions for use of the epinephrine |
auto-injectors. The Department may establish any additional |
|
requirements an authorized entity must follow under this Act. |
(c) An employee or agent of an authorized entity or other |
individual who has completed training under subsection (d) of |
this Section may: |
(1) provide an epinephrine auto-injector to any |
individual on the property of the authorized entity whom |
the employee, agent, or other individual believes in good |
faith is experiencing anaphylaxis, or to the parent, |
guardian, or caregiver of such individual, for immediate |
administration, regardless of whether the individual has a |
prescription for an epinephrine auto-injector or has |
previously been diagnosed with an allergy; or |
(2) administer an epinephrine auto-injector to any |
individual on the property of the authorized entity whom |
the employee, agent, or other individual believes in good |
faith is experiencing anaphylaxis, regardless of whether |
the individual has a prescription for an epinephrine |
auto-injector or has previously been diagnosed with an |
allergy. |
(d) An employee, agent, or other individual authorized must |
complete an anaphylaxis training program before he or she is |
able to provide or administer an epinephrine auto-injector |
under this Section. Such training shall be valid for a period |
of 2 years and shall be conducted by a nationally recognized |
organization experienced in training laypersons in emergency |
health treatment. The Department shall include links to |
|
training providers' websites on its website. |
Training shall include, but is not limited to: |
(1) how to recognize signs and symptoms of an allergic |
reaction, including anaphylaxis; |
(2) how to administer an epinephrine auto-injector; |
and |
(3) a test demonstrating competency of the knowledge |
required to recognize anaphylaxis and administer an |
epinephrine auto-injector. |
Training may also include, but is not limited to: |
(A) a review of high-risk areas on the authorized |
entity's property and its related facilities; |
(B) steps to take to prevent exposure to allergens; |
(C) emergency follow-up procedures; and |
(D) other criteria as determined in rules adopted |
pursuant to this Act. |
Training may be conducted either online or in person. The |
Department shall approve training programs and list permitted |
training programs on the Department's Internet website. |
Section 15. Costs. Whichever entity initiates the process |
of obtaining undesignated epinephrine auto-injectors and |
providing training to personnel for carrying and administering |
undesignated epinephrine auto-injectors shall pay for the |
costs of the undesignated epinephrine auto-injectors. |
|
Section 20. Limitations. The use of an undesignated |
epinephrine auto-injector in accordance with the requirements |
of this Act does not constitute the practice of medicine or any |
other profession that requires medical licensure. |
Nothing in this Act shall limit the amount of epinephrine |
auto-injectors that an authorized entity or individual may |
carry or maintain a supply of. |
Section 85. Rulemaking. The Department shall adopt any |
rules necessary to implement and administer this Act. |
Section 87. The State Police Act is amended by adding |
Section 40 as follows: |
(20 ILCS 2610/40 new) |
Sec. 40. Training; administration of epinephrine. |
(a) This Section, along with Section 10.19 of the Illinois |
Police Training Act, may be referred to as the Annie LeGere |
Law. |
(b) For the purposes of this Section, "epinephrine |
auto-injector" means a single-use device used for the automatic |
injection of a pre-measured dose of epinephrine into the human |
body prescribed in the name of the Department. |
(c) The Department may conduct or approve a training |
program for State Police officers to recognize and respond to |
anaphylaxis, including, but not limited to: |
|
(1) how to recognize symptoms of an allergic reaction; |
(2) how to respond to an emergency involving an |
allergic reaction; |
(3) how to administer an epinephrine auto-injector; |
(4) how to respond to an individual with a known |
allergy as well as an individual with a previously unknown |
allergy; |
(5) a test demonstrating competency of the knowledge |
required to recognize anaphylaxis and administer an |
epinephrine auto-injector; and |
(6) other criteria as determined in rules adopted by |
the Department. |
(d) The Department may authorize a State Police officer who |
has completed the training program under subsection (c) to |
carry, administer, or assist with the administration of |
epinephrine auto-injectors whenever he or she is performing |
official duties. |
(e) The Department must establish a written policy to |
control the acquisition, storage, transportation, |
administration, and disposal of epinephrine auto-injectors |
before it allows any State Police officer to carry and |
administer epinephrine auto-injectors. |
(f) A physician, physician's assistant with prescriptive |
authority, or advanced practice registered nurse with |
prescriptive authority may provide a standing protocol or |
prescription for epinephrine auto-injectors in the name of the |
|
Department to be maintained for use when necessary. |
(g) When a State Police officer administers epinephrine |
auto-injector in good faith, the officer and the Department, |
and its employees and agents, incur no liability, except for |
willful and wanton conduct, as a result of any injury or death |
arising from the use of an epinephrine auto-injector. |
Section 88. The Illinois Police Training Act is amended by |
adding Section 10.19 as follows: |
(50 ILCS 705/10.19 new) |
Sec. 10.19. Training; administration of epinephrine. |
(a) This Section, along with Section 40 of the State Police |
Act, may be referred to as the Annie LeGere Law. |
(b) For purposes of this Section, "epinephrine |
auto-injector" means a single-use device used for the automatic |
injection of a pre-measured dose of epinephrine into the human |
body prescribed in the name of a local governmental agency. |
(c) The Board shall conduct or approve an optional advanced |
training program for police officers to recognize and respond |
to anaphylaxis, including the administration of an epinephrine |
auto-injector. The training must include, but is not limited |
to: |
(1) how to recognize symptoms of an allergic reaction; |
(2) how to respond to an emergency involving an |
allergic reaction; |
|
(3) how to administer an epinephrine auto-injector; |
(4) how to respond to an individual with a known |
allergy as well as an individual with a previously unknown |
allergy; |
(5) a test demonstrating competency of the knowledge |
required to recognize anaphylaxis and administer an |
epinephrine auto-injector; and |
(6) other criteria as determined in rules adopted by |
the Board. |
(d) A local governmental agency may authorize a police |
officer who has completed an optional advanced training program |
under subsection (c) to carry, administer, or assist with the |
administration of epinephrine auto-injectors provided by the |
local governmental agency whenever he or she is performing |
official duties. |
(e) A local governmental agency that authorizes its |
officers to carry and administer epinephrine auto-injectors |
under subsection (d) must establish a policy to control the |
acquisition, storage, transportation, administration, and |
disposal of epinephrine auto-injectors and to provide |
continued training in the administration of epinephrine |
auto-injectors. |
(f) A physician, physician's assistant with prescriptive |
authority, or advanced practice registered nurse with |
prescriptive authority may provide a standing protocol or |
prescription for epinephrine auto-injectors in the name of a |
|
local governmental agency to be maintained for use when |
necessary. |
(g) When a police officer administers an epinephrine |
auto-injector in good faith, the police officer and local |
governmental agency, and its employees and agents, incur no |
liability, except for willful and wanton conduct, as a result |
of any injury or death arising from the use of an epinephrine |
auto-injector. |
Section 90. The School Code is amended by changing Section |
22-30 as follows:
|
(105 ILCS 5/22-30)
|
Sec. 22-30. Self-administration and self-carry of asthma |
medication and epinephrine auto-injectors; administration of |
undesignated epinephrine auto-injectors; administration of an |
opioid antagonist.
|
(a) For the purpose of this Section only, the following |
terms shall have the meanings set forth below:
|
"Asthma inhaler" means a quick reliever asthma inhaler. |
"Epinephrine auto-injector" means a single-use device used |
for the automatic injection of a pre-measured dose of |
epinephrine into the human body.
|
"Asthma medication" means a medicine, prescribed by (i) a |
physician
licensed to practice medicine in all its branches,
|
(ii) a licensed physician assistant with prescriptive |
|
authority, or (iii) a licensed advanced practice
nurse with |
prescriptive authority
for a pupil that pertains to the pupil's
|
asthma and that has an individual prescription label.
|
"Opioid antagonist" means a drug that binds to opioid |
receptors and blocks or inhibits the effect of opioids acting |
on those receptors, including, but not limited to, naloxone |
hydrochloride or any other similarly acting drug approved by |
the U.S. Food and Drug Administration. |
"School nurse" means a registered nurse working in a school |
with or without licensure endorsed in school nursing. |
"Self-administration" means a pupil's discretionary use of |
his or
her prescribed asthma medication or epinephrine |
auto-injector.
|
"Self-carry" means a pupil's ability to carry his or her |
prescribed asthma medication or epinephrine auto-injector. |
"Standing protocol" may be issued by (i) a physician |
licensed to practice medicine in all its branches, (ii) a |
licensed physician assistant with prescriptive authority, or |
(iii) a licensed advanced practice nurse with prescriptive |
authority . |
"Trained personnel" means any school employee or volunteer |
personnel authorized in Sections 10-22.34, 10-22.34a, and |
10-22.34b of this Code who has completed training under |
subsection (g) of this Section to recognize and respond to |
anaphylaxis. |
"Undesignated epinephrine auto-injector" means an |
|
epinephrine auto-injector prescribed in the name of a school |
district, public school, or nonpublic school. |
(b) A school, whether public or nonpublic, must permit the
|
self-administration and self-carry of asthma
medication by a |
pupil with asthma or the self-administration and self-carry of |
an epinephrine auto-injector by a pupil, provided that:
|
(1) the parents or
guardians of the pupil provide to |
the school (i) written
authorization from the parents or |
guardians for (A) the self-administration and self-carry |
of asthma medication or (B) the self-carry of asthma |
medication or (ii) for (A) the self-administration and |
self-carry of an epinephrine auto-injector or (B) the |
self-carry of an epinephrine auto-injector, written |
authorization from the pupil's physician, physician |
assistant, or advanced practice nurse; and
|
(2) the
parents or guardians of the pupil provide to |
the school (i) the prescription label, which must contain |
the name of the asthma medication, the prescribed dosage, |
and the time at which or circumstances under which the |
asthma medication is to be administered, or (ii) for the |
self-administration or self-carry of an epinephrine |
auto-injector, a
written
statement from the pupil's |
physician, physician assistant, or advanced practice
nurse |
containing
the following information:
|
(A) the name and purpose of the epinephrine |
auto-injector;
|
|
(B) the prescribed dosage; and
|
(C) the time or times at which or the special |
circumstances
under which the epinephrine |
auto-injector is to be administered.
|
The information provided shall be kept on file in the office of |
the school
nurse or,
in the absence of a school nurse, the |
school's administrator.
|
(b-5) A school district, public school, or nonpublic school |
may authorize the provision of a student-specific or |
undesignated epinephrine auto-injector to a student or any |
personnel authorized under a student's Individual Health Care |
Action Plan, Illinois Food Allergy Emergency Action Plan and |
Treatment Authorization Form, or plan pursuant to Section 504 |
of the federal Rehabilitation Act of 1973 to administer an |
epinephrine auto-injector to the student, that meets the |
student's prescription on file. |
(b-10) The school district, public school, or nonpublic |
school may authorize a school nurse or trained personnel to do |
the following: (i) provide an undesignated epinephrine |
auto-injector to a student for self-administration only or any |
personnel authorized under a student's Individual Health Care |
Action Plan, Illinois Food Allergy Emergency Action Plan and |
Treatment Authorization Form, or plan pursuant to Section 504 |
of the federal Rehabilitation Act of 1973 to administer to the |
student, that meets the student's prescription on file; (ii) |
administer an undesignated epinephrine auto-injector that |
|
meets the prescription on file to any student who has an |
Individual Health Care Action Plan, Illinois Food Allergy |
Emergency Action Plan and Treatment Authorization Form, or plan |
pursuant to Section 504 of the federal Rehabilitation Act of |
1973 that authorizes the use of an epinephrine auto-injector; |
(iii) administer an undesignated epinephrine auto-injector to |
any person that the school nurse or trained personnel in good |
faith believes is having an anaphylactic reaction; and (iv) |
administer an opioid antagonist to any person that the school |
nurse or trained personnel in good faith believes is having an |
opioid overdose. |
(c) The school district, public school, or nonpublic school |
must inform the parents or
guardians of the
pupil, in writing, |
that the school district, public school, or nonpublic school |
and its
employees and
agents, including a physician, physician |
assistant, or advanced practice nurse providing standing |
protocol or prescription for school epinephrine |
auto-injectors,
are to incur no liability or professional |
discipline, except for willful and wanton conduct, as a result
|
of any injury arising from the
administration of asthma |
medication, an epinephrine auto-injector, or an opioid |
antagonist regardless of whether authorization was given by the |
pupil's parents or guardians or by the pupil's physician, |
physician assistant, or advanced practice nurse. The parents or |
guardians
of the pupil must sign a statement acknowledging that |
the school district, public school, or nonpublic school and its |
|
employees and agents are to incur no liability, except for |
willful and wanton
conduct, as a result of any injury arising
|
from the
administration of asthma medication, an epinephrine |
auto-injector, or an opioid antagonist regardless of whether |
authorization was given by the pupil's parents or guardians or |
by the pupil's physician, physician assistant, or advanced |
practice nurse and that the parents or
guardians must indemnify |
and hold harmless the school district, public school, or |
nonpublic
school and
its
employees and agents against any |
claims, except a claim based on willful and
wanton conduct, |
arising out of the
administration of asthma medication, an |
epinephrine auto-injector, or an opioid antagonist regardless |
of whether authorization was given by the pupil's parents or |
guardians or by the pupil's physician, physician assistant, or |
advanced practice nurse. |
(c-5) When a school nurse or trained personnel administers |
an undesignated epinephrine auto-injector to a person whom the |
school nurse or trained personnel in good faith believes is |
having an anaphylactic reaction , or administers an opioid |
antagonist to a person whom the school nurse or trained |
personnel in good faith believes is having an opioid overdose, |
notwithstanding the lack of notice to the parents or guardians |
of the pupil or the absence of the parents or guardians signed |
statement acknowledging no liability, except for willful and |
wanton conduct, the school district, public school, or |
nonpublic school and its employees and agents, and a physician, |
|
a physician assistant, or an advanced practice nurse providing |
standing protocol or prescription for undesignated epinephrine |
auto-injectors, are to incur no liability or professional |
discipline, except for willful and wanton conduct, as a result |
of any injury arising from the use of an undesignated |
epinephrine auto-injector or the use of an opioid antagonist |
regardless of whether authorization was given by the pupil's |
parents or guardians or by the pupil's physician, physician |
assistant, or advanced practice nurse.
|
(d) The permission for self-administration and self-carry |
of asthma medication or the self-administration and self-carry |
of an epinephrine auto-injector is effective
for the school |
year for which it is granted and shall be renewed each
|
subsequent school year upon fulfillment of the requirements of |
this
Section.
|
(e) Provided that the requirements of this Section are |
fulfilled, a
pupil with asthma may self-administer and |
self-carry his or her asthma medication or a pupil may |
self-administer and self-carry an epinephrine auto-injector |
(i) while in
school, (ii) while at a school-sponsored activity, |
(iii) while under the
supervision of
school personnel, or (iv) |
before or after normal school activities, such
as while in |
before-school or after-school care on school-operated
property |
or while being transported on a school bus .
|
(e-5) Provided that the requirements of this Section are |
fulfilled, a school nurse or trained personnel may administer |
|
an undesignated epinephrine auto-injector to any person whom |
the school nurse or trained personnel in good faith believes to |
be having an anaphylactic reaction (i) while in school, (ii) |
while at a school-sponsored activity, (iii) while under the |
supervision of school personnel, or (iv) before or after normal |
school activities, such
as while in before-school or |
after-school care on school-operated property or while being |
transported on a school bus . A school nurse or trained |
personnel may carry undesignated epinephrine auto-injectors on |
his or her person while in school or at a school-sponsored |
activity. |
(e-10) Provided that the requirements of this Section are |
fulfilled, a school nurse or trained personnel may administer |
an opioid antagonist to any person whom the school nurse or |
trained personnel in good faith believes to be having an opioid |
overdose (i) while in school, (ii) while at a school-sponsored |
activity, (iii) while under the supervision of school |
personnel, or (iv) before or after normal school activities, |
such as while in before-school or after-school care on |
school-operated property. A school nurse or trained personnel |
may carry an opioid antagonist on their person while in school |
or at a school-sponsored activity. |
(f) The school district, public school, or nonpublic school |
may maintain a supply of undesignated epinephrine |
auto-injectors in any secure location that is accessible |
before, during, and after school where an allergic person is |
|
most at risk, including, but not limited to, classrooms and |
lunchrooms. A physician, a physician assistant who has been |
delegated prescriptive authority in accordance with Section |
7.5 of the Physician Assistant Practice Act of 1987, or an |
advanced practice nurse who has been delegated prescriptive |
authority in accordance with Section 65-40 of the Nurse |
Practice Act may prescribe undesignated epinephrine |
auto-injectors in the name of the school district, public |
school, or nonpublic school to be maintained for use when |
necessary. Any supply of epinephrine auto-injectors shall be |
maintained in accordance with the manufacturer's instructions. |
The school district, public school, or nonpublic school may |
maintain a supply of an opioid antagonist in any secure |
location where an individual may have an opioid overdose. A |
health care professional who has been delegated prescriptive |
authority for opioid antagonists in accordance with Section |
5-23 of the Alcoholism and Other Drug Abuse and Dependency Act |
may prescribe opioid antagonists in the name of the school |
district, public school, or nonpublic school, to be maintained |
for use when necessary. Any supply of opioid antagonists shall |
be maintained in accordance with the manufacturer's |
instructions. |
(f-3) Whichever entity initiates the process of obtaining |
undesignated epinephrine auto-injectors and providing training |
to personnel for carrying and administering undesignated |
epinephrine auto-injectors shall pay for the costs of the |
|
undesignated epinephrine auto-injectors. |
(f-5) Upon any administration of an epinephrine |
auto-injector, a school district, public school, or nonpublic |
school must immediately activate the EMS system and notify the |
student's parent, guardian, or emergency contact, if known. |
Upon any administration of an opioid antagonist, a school |
district, public school, or nonpublic school must immediately |
activate the EMS system and notify the student's parent, |
guardian, or emergency contact, if known. |
(f-10) Within 24 hours of the administration of an |
undesignated epinephrine auto-injector, a school district, |
public school, or nonpublic school must notify the physician, |
physician assistant, or advanced advance practice nurse who |
provided the standing protocol or prescription for the |
undesignated epinephrine auto-injector of its use. |
Within 24 hours after the administration of an opioid |
antagonist, a school district, public school, or nonpublic |
school must notify the health care professional who provided |
the prescription for the opioid antagonist of its use. |
(g) Prior to the administration of an undesignated |
epinephrine auto-injector, trained personnel must submit to |
their his or her school's administration proof of completion of |
a training curriculum to recognize and respond to anaphylaxis |
that meets the requirements of subsection (h) of this Section. |
Training must be completed annually. Trained personnel must |
also submit to his or her school's administration proof of |
|
cardiopulmonary resuscitation and automated external |
defibrillator certification. The school district, public |
school, or nonpublic school must maintain records related to |
the training curriculum and trained personnel. |
Prior to the administration of an opioid antagonist, |
trained personnel must submit to their school's administration |
proof of completion of a training curriculum to recognize and |
respond to an opioid overdose, which curriculum must meet the |
requirements of subsection (h-5) of this Section. Training must |
be completed annually. Trained personnel must also submit to |
the school's administration proof of cardiopulmonary |
resuscitation and automated external defibrillator |
certification. The school district, public school, or |
nonpublic school must maintain records relating to the training |
curriculum and the trained personnel. |
(h) A training curriculum to recognize and respond to |
anaphylaxis, including the administration of an undesignated |
epinephrine auto-injector, may be conducted online or in |
person. |
Training shall include, but is not limited to: |
(1) how to recognize signs and symptoms of an allergic |
reaction, including anaphylaxis; |
(2) how to administer an epinephrine auto-injector; |
and |
(3) a test demonstrating competency of the knowledge |
required to recognize anaphylaxis and administer an |
|
epinephrine auto-injector. |
Training may also include, but is not limited to: |
(A) a review of high-risk areas within a school and its |
related facilities; |
(B) steps to take to prevent exposure to allergens; |
(C) emergency follow-up procedures; |
(D) how to respond to a student with a known allergy, |
as well as a student with a previously unknown allergy; and |
(E) other criteria as determined in rules adopted |
pursuant to this Section. It must include, but is not |
limited to: |
(1) how to recognize symptoms of an allergic reaction; |
(2) a review of high-risk areas within the school and |
its related facilities; |
(3) steps to take to prevent exposure to allergens; |
(4) how to respond to an emergency involving an |
allergic reaction; |
(5) how to administer an epinephrine auto-injector; |
(6) how to respond to a student with a known allergy as |
well as a student with a previously unknown allergy; |
(7) a test demonstrating competency of the knowledge |
required to recognize anaphylaxis and administer an |
epinephrine auto-injector; and |
(8) other criteria as determined in rules adopted |
pursuant to this Section. |
In consultation with statewide professional organizations |
|
representing physicians licensed to practice medicine in all of |
its branches, registered nurses, and school nurses, the State |
Board of Education shall make available resource materials |
consistent with criteria in this subsection (h) for educating |
trained personnel to recognize and respond to anaphylaxis. The |
State Board may take into consideration the curriculum on this |
subject developed by other states, as well as any other |
curricular materials suggested by medical experts and other |
groups that work on life-threatening allergy issues. The State |
Board is not required to create new resource materials. The |
State Board shall make these resource materials available on |
its Internet website. |
(h-5) A training curriculum to recognize and respond to an |
opioid overdose, including the administration of an opioid |
antagonist, may be conducted online or in person. The training |
must comply with any training requirements under Section 5-23 |
of the Alcoholism and Other Drug Abuse and Dependency Act and |
the corresponding rules. It must include, but is not limited |
to: |
(1) how to recognize symptoms of an opioid overdose; |
(2) information on drug overdose prevention and |
recognition; |
(3) how to perform rescue breathing and resuscitation; |
(4) how to respond to an emergency involving an opioid |
overdose; |
(5) opioid antagonist dosage and administration; |
|
(6) the importance of calling 911; |
(7) care for the overdose victim after administration |
of the overdose antagonist; |
(8) a test demonstrating competency of the knowledge |
required to recognize an opioid overdose and administer a |
dose of an opioid antagonist; and |
(9) other criteria as determined in rules adopted |
pursuant to this Section. |
(i) Within 3 days after the administration of an |
undesignated epinephrine auto-injector by a school nurse, |
trained personnel, or a student at a school or school-sponsored |
activity, the school must report to the State Board of |
Education in a form and manner prescribed by the State Board |
the following information: |
(1) age and type of person receiving epinephrine |
(student, staff, visitor); |
(2) any previously known diagnosis of a severe allergy; |
(3) trigger that precipitated allergic episode; |
(4) location where symptoms developed; |
(5) number of doses administered; |
(6) type of person administering epinephrine (school |
nurse, trained personnel, student); and |
(7) any other information required by the State Board. |
If a school district, public school, or nonpublic school |
maintains or has an independent contractor providing |
transportation to students who maintains a supply of |
|
undesignated epinephrine auto-injectors, then the school |
district, public school, or nonpublic school must report that |
information to the State Board of Education upon adoption or |
change of the policy of the school district, public school, |
nonpublic school, or independent contractor, in a manner as |
prescribed by the State Board. The report must include the |
number of undesignated epinephrine auto-injectors in supply. |
(i-5) Within 3 days after the administration of an opioid |
antagonist by a school nurse or trained personnel, the school |
must report to the State Board, in a form and manner prescribed |
by the State Board, the following information: |
(1) the age and type of person receiving the opioid |
antagonist (student, staff, or visitor); |
(2) the location where symptoms developed; |
(3) the type of person administering the opioid |
antagonist (school nurse or trained personnel); and |
(4) any other information required by the State Board. |
(j) By October 1, 2015 and every year thereafter, the State |
Board of Education shall submit a report to the General |
Assembly identifying the frequency and circumstances of |
epinephrine administration during the preceding academic year. |
Beginning with the 2017 report, the report shall also contain |
information on which school districts, public schools, and |
nonpublic schools maintain or have independent contractors |
providing transportation to students who maintain a supply of |
undesignated epinephrine auto-injectors. This report shall be |
|
published on the State Board's Internet website on the date the |
report is delivered to the General Assembly. |
On or before October 1, 2016 and every year thereafter, the |
State Board shall submit a report to the General Assembly and |
the Department of Public Health identifying the frequency and |
circumstances of opioid antagonist administration during the |
preceding academic year. This report shall be published on the |
State Board's Internet website on the date the report is |
delivered to the General Assembly. |
(k) The State Board of Education may adopt rules necessary |
to implement this Section. |
(l) Nothing in this Section shall limit the amount of |
epinephrine auto-injectors that any type of school or student |
may carry or maintain a supply of. |
(Source: P.A. 98-795, eff. 8-1-14; 99-173, eff. 7-29-15; |
99-480, eff. 9-9-15; revised 10-13-15.)
|
Section 95. The Illinois Food, Drug and Cosmetic Act is |
amended by changing Section 3.21 as follows:
|
(410 ILCS 620/3.21) (from Ch. 56 1/2, par. 503.21)
|
Sec. 3.21. Except as authorized by this Act, the Illinois |
Controlled Substances
Act, the Pharmacy Practice Act, the |
Dental Practice Act, the Medical
Practice Act of 1987, the |
Veterinary Medicine and Surgery Practice Act of
2004, the |
Podiatric Medical Practice Act of 1987, or Section 22-30 of the |
|
School Code, Section 40 of the State Police Act, Section 10.19 |
of the Illinois Police Training Act, or the Epinephrine |
Auto-Injector Act, to sell or dispense a
prescription drug |
without a prescription.
|
(Source: P.A. 99-78, eff. 7-20-15.)
|
Section 100. The State Mandates Act is amended by adding |
Section 8.40 as follows: |
(30 ILCS 805/8.40 new) |
Sec. 8.40. Exempt mandate. Notwithstanding Sections 6 and 8 |
of this Act, no reimbursement by the State is required for the |
implementation of any mandate created by Section 40 of the |
State Police Act and Section 10.19 of the Illinois Police |
Training Act. |